idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
25.03.2025 13:41

New potential target for colon cancer therapy

Frederike Buhse Presse- und Öffentlichkeitsarbeit
Exzellenzcluster Präzisionsmedizin für chronische Entzündungserkrankungen

    Research by the Cluster of Excellence PMI and the DFG Research Unit “miTarget” shows that a protein frequently found in the inflamed intestine could play an important role in the development of cancer / publication in Cancer Communications

    People with inflammatory bowel disease (IBD) also have an increased risk of developing colorectal cancer. However, the exact mechanisms behind this are still largely unknown. Researchers from the Cluster of Excellence “Precision Medicine in Chronic Inflammation” (PMI) and the DFG Research Unit “miTarget” are therefore trying to better understand this connection. A Kiel research team has now found that a protein that occurs unusually frequently in patients with IBD is also associated with colorectal cancer. If the responsible gene is removed from cancer cells, so that the protein can no longer be produced, tumor growth is inhibited. The researchers, led by PD Dr. Felix Sommer from the Institute of Clinical Molecular Biology (IKMB) of the Faculty of Medicine at Kiel University (CAU) and the University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, recently published their results in the journal Cancer Communications. The work was carried out in close cooperation within PMI with the research groups of Professor Philip Rosenstiel (IKMB), Professor Jan Rupp (UKSH Lübeck, Institute of Medical Microbiology), Professor Christoph Kaleta (Institute of Experimental Medicine, IEM), Professor Andreas Tholey (IEM) and Professor Christoph Röcken (UKSH Kiel, Institute of Pathology).

    Protein HKDC1 influences tumor growth in the intestine

    The protein HKDC1 (hexokinase domain containing 1) belongs to the hexokinase family along with four other similar enzymes. These are enzymes that play a particularly important role in carbohydrate metabolism in the body. Previous research had already shown that HKDC1 plays a role in some types of cancer. However, a role within colorectal cancer was not known. In addition, scientists from the PMI Cluster of Excellence, led by Professor Rosenstiel, had already shown that HKDC1 is upregulated in people with IBD. “In addition, we know that HKDC1 is mainly found in the intestine. We therefore wondered what it does there and whether it has an influence on the development of cancer in the gut,” reports one of the two first authors, PhD student Lea Järke from the group ‘Functional Host Microbiome Research’ at the IKMB.

    PD Dr. Felix Sommer's team therefore conducted various experiments to investigate the effects of removing the gene responsible for producing the protein in colon cancer cells. If it is no longer present, the cell can no longer produce the protein. They carried out the experiments in cell culture, in organoids - artificial intestinal models in a petri dish - and in mouse models. “Among other things, we were able to observe that the cancer cells without HKDC1 no longer divide unhindered, they become more susceptible to external signals that lead to their death and, as a result, the tumors either do not develop at all or only to a greatly reduced extent,” reports the second first author, PhD student Saskia Weber-Stiehl, also from the ‘Functional Host Microbiome Research’ group at the IKMB. Further research must show whether the results may also be transferable to humans.

    Blocking the enzyme could help IBD and colorectal cancer

    The elevated production of HKDC1 in people with IBD could therefore explain why these patients are also more likely to develop colorectal cancer. The findings could be relevant for a possible therapy: both colon cancer and IBD could be influenced if HKDC1 is blocked - for example by chemical inhibitors or by targeted interventions in the microbiome. It is known that some cancer therapies are dependent on the microbiome. This is because the bacteria in the gut produce enzymes, for example, which can switch off active substances in cancer drugs or make them active in the first place. In addition, the researchers from Kiel have already shown for other members of the hexokinase family that these can be regulated by the microbiome. “In the case of HKDC1, it is also conceivable that the microbiome in the intestine influences the production of the enzyme. This is the subject of our current research,” says Sommer. “In the long term, we want to find out whether we can suppress hexokinase and thus tumor growth by modulating the microbiome,” Sommer continues.


    Wissenschaftliche Ansprechpartner:

    PD Dr. Felix Sommer
    Institute of Clinical Molecular Biology, Kiel University and UKSH
    Medical Faculty, Kiel University
    Tel.: +49-500-15146
    Mail: f.sommer@ikmb-uni-kiel.de


    Originalpublikation:

    L. Järke*, S. Weber-Stiehl* et al.: Deletion of epithelial HKDC1 decelerates cellular proliferation and impairs mitochondrial function of tumorous epithelial cells thereby protecting from intestinal. Cancer Communications, 2025. https://doi.org/10.1002/cac2.70022
    *The two authors contributed equally to the work.


    Bilder

    Lead author of the research work PD Dr. Felix Sommer, head of the “Functional Host Microbiome Research” working group at the Institute of Clinical Molecular Biology (IKMB), CAU and UKSH, Campus Kiel.
    Lead author of the research work PD Dr. Felix Sommer, head of the “Functional Host Microbiome Resear ...
    S. Klahn
    Cluster of Excellence PMI

    If the enzyme HKDC1 was missing in the experiments in cell culture, organoids and mouse models, tumors could not develop at all or only to a greatly reduced extent.
    If the enzyme HKDC1 was missing in the experiments in cell culture, organoids and mouse models, tumo ...
    AI generated
    Felix Sommer lab, Kiel University


    Merkmale dieser Pressemitteilung:
    Journalisten, Wissenschaftler
    Biologie, Chemie, Ernährung / Gesundheit / Pflege, Medizin
    überregional
    Forschungsergebnisse, Wissenschaftliche Publikationen
    Englisch


     

    Lead author of the research work PD Dr. Felix Sommer, head of the “Functional Host Microbiome Research” working group at the Institute of Clinical Molecular Biology (IKMB), CAU and UKSH, Campus Kiel.


    Zum Download

    x

    If the enzyme HKDC1 was missing in the experiments in cell culture, organoids and mouse models, tumors could not develop at all or only to a greatly reduced extent.


    Zum Download

    x

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).